Publications by authors named "Zelei Yu"

Claim this Profile
A
A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer.
Ge Li, Shan-Shan Lin, Ze-Lei Yu, Xin-Hua Wu, Jing-Wen Liu, Quan-Yu Liu, Yuan-Ling Tang

Biochem Pharmacol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of CN0 as a novel proteolysis-targeting chimera (PROTAC) degrader of PARP1 that can activate the cGAS/STING immunity pathway combined with daunorubicin.
Shanshan Lin, Guihui Tu, Zelei Yu, Qingna Jiang, Lingyu Zhang, Quanyu Liu

Bioorg Med Chem· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of novel dual target inhibitors of PARP and EGFR and their antitumor activities in triple negative breast cancers.
Shanshan Lin, Xiao Zhang, Zelei Yu, Xiuwang Huang, Jianhua Xu

Bioorg Med Chem· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of BP3 as an efficacious proteolysis targeting chimera (PROTAC) degrader of HSP90 for treating breast cancer.
Quanyu Liu, Guihui Tu, Yan Hu, Qingna Jiang, Jingwen Liu, Zelei Yu, Yuanling Tang

Eur J Med Chem· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MiR-519d-5p modulates the sensitivity of breast cancer to chemotherapy by forming a negative feedback loop with RELA.
Ding Li, Tingting Wang, Zelei Yu, Yi Zhang, Xuan Wu

Ann Transl Med· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of the novel LincRNA uc002jit.1 in NF-kB-mediated DNA damage repair in acute myeloid leukemia cells.
Ding Li, Zelei Yu, Tingting Wang, Yi Li, Xianling Chen

Exp Cell Res· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of novel dual target inhibitors of PARP and HSP90 and their antitumor activities.
Shanshan Lin, LingYu Zhang, Xiao Zhang, Zelei Yu, Xiuwang Huang

Bioorg Med Chem· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis